How do you close out open CAPAs for good and pass every inspection without an overdue backlog?
We build CAPA systems in line with ICH Q10 (Pharmaceutical Quality System), EU GMP and ISO 13485:2016, in which every corrective and preventive action follows a robust root-cause analysis, is implemented on schedule and is verified for effectiveness. The sore point is rarely the individual action, but the missing root-cause analysis: correcting symptoms instead of eliminating causes produces recurring deviations and a growing backlog of overdue CAPAs, and every inspector reads exactly this pattern as a weakness of the entire quality system.
- Pharma
- Biotech
- MedTech
- IVD
Overview
Why do CAPA systems fail in practice?
CAPA systems across GxP, from Pharma to medical devices · ICH Q10, EU GMP Guide Part I, 21 CFR Part 820.100, ISO 13485:2016
Last updated: 2026-06-13
A CAPA is not a form, but the mechanism by which a quality system learns from deviations. It is precisely at this learning step that most systems break down. Four patterns recur across Pharma, Biotech, MedTech and IVD:
- Treating symptoms instead of analyzing causes: if the root cause is not determined robustly, the action only corrects the symptom. The deviation returns, and ISO 13485:2016 Section 8.5.2 as well as 21 CFR Part 820.100 explicitly require that the cause of the nonconformity be determined and eliminated.
- Overdue backlog: CAPAs not closed out beyond their planned due date are one of the most common inspection findings. A growing backlog shows that the pharmaceutical quality system under EU GMP Guide Part I Chapter 1 is not controlling its own actions.
- Missing effectiveness verification: a CAPA is only considered effective once it has been demonstrated that the cause has been eliminated. If it is closed without an effectiveness check, the evidence that ICH Q10 expects as part of the CAPA system is missing.
- No link to risk and trending: without a connection to quality risk management under ICH Q9(R1) and without trending of recurring deviations, every CAPA remains an isolated case rather than revealing systematic weaknesses.
Services
How we support you
CAPA System Design & Process Build
Building a CAPA process with defined triggers, escalation levels, responsibilities and risk assessment in line with ICH Q9(R1). Deliverable: an SOP for CAPA management including the decision logic for when a deviation triggers a CAPA and when a correction is sufficient.
Root-Cause Analysis & Problem Solving
Facilitated root-cause analysis using structured methods (5-Why, Ishikawa, Fault Tree). Deliverable: a documented root-cause analysis for each CAPA with a traceable link between the determined cause and the derived action in line with 21 CFR Part 820.100 and ISO 13485:2016 Section 8.5.2.
CAPA Backlog Clearance
Review, risk prioritization and resolution of overdue and open CAPAs. Deliverable: a prioritized backlog list with status assessment, a closure plan and cleanly documented closures that withstand an inspection.
Effectiveness Verification & Trending
Definition of measurable effectiveness criteria and building a trending capability for recurring deviations. Deliverable: an effectiveness-check concept with acceptance criteria per CAPA, plus a trending report as input for the management review in line with ICH Q10.
Inspection Readiness for CAPA
Preparing the CAPA system for authority and notified body audits, including a mock review of open cases. Deliverable: a gap list of critical CAPAs and a defensible set of example cases for the inspection.
Learn more →How we work together
What it comes down to
A CAPA is only as good as the root-cause analysis it is based on. The sequence is decisive: first the deviation is assessed on a risk basis in line with ICH Q9(R1), then the root cause is separated from symptom and trigger, and only after that are actions planned. Reversing this sequence and defining actions first corrects the symptom and leaves the cause in place. The result is a recurring deviation that is linked to the first CAPA in the audit and turns two isolated cases into a systematic finding.
The critical point is effectiveness verification, not implementation. An action can be worked through quickly, but the evidence that the cause has actually been eliminated requires predefined acceptance criteria and an observation period. This is exactly where the backlog arises: CAPAs that have been implemented but never verified for effectiveness with defensible evidence remain open and grow into the overdue inventory that ICH Q10 and the EU GMP Guide Part I read as a weakness of the quality system. We therefore front-load the effort into root-cause analysis and the definition of measurable effectiveness criteria, because there every later closure becomes inexpensive instead of becoming costly in the backlog.
Our approach
Our approach
Step
Result
Problem Identification & Assessment
Deviation recorded, severity and CAPA need assessed on a risk basis in line with ICH Q9(R1), immediate action documented.
Root-Cause Analysis
Robustly determined root cause with a traceable methodology, separated from symptom and trigger.
Action Planning
Defined corrective and preventive actions with owners, due dates and a clear link to the determined cause.
Implementation
Actions implemented and documented on schedule, affected SOPs and training updated.
Effectiveness Verification
Effectiveness check passed against predefined acceptance criteria, CAPA closed with defensible evidence.
Trending & Review
Recurring causes made visible through trending, the result fed as input into the management review in line with ICH Q10.
Common pitfalls
Where projects commonly fail
The root cause is not separated from the symptom and the trigger.
An action that only corrects the observed symptom leaves the actual cause in place, and the deviation returns as a recurring case that every inspector links to the first CAPA.
CAPAs are closed without effectiveness verification.
A closure without a documented effectiveness check against predefined criteria satisfies neither the expectation of ICH Q10 nor the evidence obligation under 21 CFR Part 820.100, and is immediately apparent in an audit.
The backlog of overdue CAPAs is managed rather than reduced.
Constantly postponed due dates signal to the inspection that the quality system under EU GMP Guide Part I Chapter 1 is not controlling its own actions. Due dates are to be set on a risk basis and met, not extended.
Every deviation generates a CAPA.
Without decision logic for when a correction is sufficient and when a CAPA with root-cause analysis is required, the system grows under its own weight. ICH Q9(R1) provides the risk-based basis for this distinction.
CAPAs from different sources run separately.
Deviations, complaints under EU GMP Guide Part I Chapter 8, audit findings and complaints all feed into the same CAPA system. If the strands remain disconnected, the trending that reveals systematic causes across individual cases is missing.
FAQ
Frequently asked questions
Sources
- ICH Q10 - Pharmaceutical Quality System (Corrective Action and Preventive Action System)
- ICH Q9(R1) - Quality Risk Management
- EU GMP Guide Part I, Chapter 1 and Chapter 8 - primary text
- 21 CFR Part 820.100 (Corrective and Preventive Action) & 21 CFR Part 211 - primary text
- ISO 13485:2016, Section 8.5.2 and 8.5.3 - corrective and preventive actions
- Source material Entourage Writer - capa-management.md
- https://theentourage.de/expertise/capa-management/ (existing page content, revised)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Related insights
All insights →Regulations & standards considered
- ICH Q10 (Pharmaceutical Quality System), Corrective Action and Preventive Action (CAPA) System
- ICH Q9(R1) (Quality Risk Management)
- EU GMP Guide Part I Chapter 1 (Pharmaceutical Quality System)
- EU GMP Guide Part I Chapter 8 (Complaints, Quality Defects and Product Recalls)
- 21 CFR Part 211 (cGMP for Finished Pharmaceuticals)
- 21 CFR Part 820, 820.100 (Corrective and Preventive Action)
- ISO 13485:2016, Section 8.5.2 (Corrective Action) & 8.5.3 (Preventive Action)
- ISO 9001:2015, Section 10.2 (Nonconformity and Corrective Action)
- EU 2017/745 (MDR)
- EU 2017/746 (IVDR)
Related topics
Deviation Management →
The deviation as the most common trigger of a CAPA, cleanly delineated
Complaint Management →
Complaints under EU GMP Guide Part I Chapter 8 as a CAPA source
Change Management →
Implementing actions from CAPAs through controlled changes
Inspection Readiness →
Closing open CAPAs with defensible evidence before the inspection
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences